Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
तुलना करने के लिए मीट्रिक्स | ESPR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधESPRपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.4x | 3.4x | −0.5x | |
PEG अनुपात | 2.65 | 0.34 | 0.00 | |
क़ीमत/बुक | −1.7x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.6x | 2.3x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 41.6% | 102.6% | 45.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 25.3% | 5.1% | अनलॉक करें |